Navigation Links
CEL-SCI Files Patent Application to Support Company's Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses
Date:6/24/2009

technology with specificity for particular Mycobacterium tuberculosis (TB) antigens can elicit immune responses that would be expected to be protective against tuberculosis and have the potential to treat swine and other H1N1 influenzas. The TB investigators presented data that showed that blood and spleen cells from immunized mice produced gamma interferon in response to the vaccine, while the cells from mice in the various control groups did not. Other recent L.E.A.P.S. data, presented by Dr. Kenneth S. Rosenthal, Professor of Microbiology, Immunology and Biochemistry at Northeastern Ohio Universities Colleges of Medicine and Pharmacy and colleagues at the 12th NFID meeting in Baltimore showed that CEL-SCI's L.E.A.P.S. vaccines can activate and cause human blood monocyte cells to become dendritic cells that secrete the IL-12 cytokine. The dendritic cells that result initiate a protective cell mediated and antibody immune response. These results were obtained for L.E.A.P.S. vaccines against herpes simplex and HIV.

The L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology. Each L.E.A.P.S. construct is composed of a T cell binding ligand (TCBL) which has previously demonstrated the ability to induce and elicit protective immunity and antigen specific antibody production in animal models.

The concept behind the L.E.A.P.S. technology is to directly mimic cell/cell interactions on the dendritic and T-cell surface with synthetic peptides. The L.E.A.P.S. constructs containing the antigenic disease epitope linked to an Immune/T-cell binding ligand (I/TCBL) can be manufactured by peptide synthesis or by covale
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CEL-SCI Signs Definitive Agreement to Raise $5 Million in Registered Direct Offering
2. CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology
3. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
4. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
5. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
6. CEL-SCI Corporation Announces 2008 Financial Results
7. CEL-SCI Corporation Releases Letter to Shareholders
8. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
9. CEL-SCI Takes Delivery of New Manufacturing Facility
10. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
11. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... San Francisco, CA (PRWEB) April 16, 2015 ... is scheduled to report first quarter results on Thursday, ... the announcement, Cytokinetics’ senior management will host a conference ... and financial results and the company’s outlook for the ... and can be accessed from the homepage and in ...
(Date:4/16/2015)... 16, 2015 According to the ... an outside source was ranked first among the ... related to lifting, pushing, pulling, holding, carrying, or ... costs. The David Round Company takes statistics like ... working hard to develop and design equipment that ...
(Date:4/16/2015)... 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... joint venture with G-treeBNT (ReGenTree LLC) has retained ... trial for the orphan disorder, neurotrophic keratopathy (NK), ... eye syndrome (DES) in the U.S.  Both trials ... this year.  Each of these eye disorders was ...
(Date:4/16/2015)... Calif. , April 16, 2015  Scientists from ... "New Drugs on the Horizon," at the American Association ... Philadelphia, PA on Sunday, April 19, 2015 ... Ph.D., Cleave,s Director of Biology, will present new in ... a first-in-class, oral inhibitor of p97, a critical enzyme ...
Breaking Biology Technology:Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3
... 30 Champions,Biotechnology, Inc. (OTC Bulletin Board: CSBR), ... platforms and tumor specific data to,enhance the value ... the fiscal year ended April 30, 2008. Full ... the Company,s Form 10-KSB available at, http://www.championsbiotechnology.com ., ...
... today announced that it has partnered with Green Mountain Energy Company ... total calculated carbon dioxide (CO2) emissions thereby enabling them to operate ... ... Mesa, CA (PRWEB) July 30, 2008 -- Alkemists Pharmaceuticals today announced ...
... announces the following Webcast:, What: Transgenomic Inc. ... Conference Call, When: Wednesday, August ... , How: Live over the Internet -- ... address above., Contact: Investor Relations, ...
Cached Biology Technology:Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results 2Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results 3Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results 4Alkemists Sets The Bar, Becoming a 'Green' Analytical Laboratory 2Alkemists Sets The Bar, Becoming a 'Green' Analytical Laboratory 3
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:3/31/2015)... , March 31, 2015   Guidepoint , ... launch of the Post-Surgical Pain Management TRACKER, part of ... tracking usage trends in the medical device and therapeutics ... to data including treatment volumes, market share, and adoption ... pain associated with joint surgery. The Post-Surgical ...
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... Organization (EMBO) and the Federation of European Biochemical ... Friedrich Miescher Institute for Biomedical Research in Basel, ... Women in Science Award. Professor Gasser has been ... stability and epigenetics and her commitment to mentoring ...
... (New York, NY) The Alfred P. Sloan ... outstanding U.S. and Canadian researchers as recipients of Sloan ... fellowships are given to early-career scientists and scholars whose ... next generation of scientific leaders. "Today,s Sloan Research ...
... DETROIT Technology to restore vision through the use ... a Wayne State University professor and scientific director of ... Eye Institute has attracted additional funding for therapy ... grant from their affiliate, National Neurovision Research Institute, to ...
Cached Biology News:Susan M. Gasser to receive the 2012 FEBS/EMBO Women in Science Award 2Sloan Research Fellowships awarded to 126 young scholars 2Wayne State-licensed technology receives grant from the Foundation Fighting Blindness 2
... Inhibitor is a recombinant protein that has been ... in the preparation of cDNA by reverse transcription, ... protein synthesis. RNA Safe Inhibitor tightly binds RNases ... range of eukaryotic RNases such as RNase A, ...
... Inhibitor (Ribonuclease inhibitor) is a ... to inhibit RNase activity. It ... endonuclease activity. , Inhibits ... RNA template , Lacks ...
... acids ,The GC-RICH PCR System, a ... proofreading polymerase, powers through templates that are ... polymerases and other blends of polymerases. The ... unique GC-RICH Resolution Solution combine to deliver ...
... of optimized cell lines in combination with ... parameters. Nucleofector Kits are only functional in ... lines can be transfected with this kit. ... in brackets in percent (Efficiency [%] / ...
Biology Products: